I am a 69‑kg insulin‑naïve patient with pancreatogenic (type 3c) diabetes on insulin glargine (Lantus) 7‑10 U nightly and rapid‑acting insulin 4‑5 U before each main meal; after using an insulin‑to‑carbohydrate ratio of 1 unit per 10 g carbohydrate my blood glucose was 351 mg/dL. How should I adjust my insulin regimen?

Immediate Insulin Regimen Adjustment for Severe Post-Prandial Hyperglycemia in Type 3c Diabetes

Your current insulin-to-carbohydrate ratio of 1:10 is profoundly inadequate, as evidenced by a post-meal glucose of 351 mg/dL; you must immediately tighten your ratio to 1:6 or 1:7 and increase your basal insulin by 2–4 units to address both prandial and fasting hyperglycemia in the context of pancreatogenic diabetes. 1

Understanding Type 3c (Pancreatogenic) Diabetes

• Type 3c diabetes results from pancreatic disease and is characterized by both insulin and glucagon deficiency, leading to marked glucose variability, increased insulin requirements, and heightened hypoglycemia risk compared with type 1 or type 2 diabetes. 2, 3
• Patients with pancreatogenic diabetes exhibit hepatic insulin resistance due to deficiencies of insulin and pancreatic polypeptide, requiring higher insulin doses than predicted by standard formulas. 3
• The combination of impaired counter-regulatory responses (due to glucagon deficiency) and variable insulin absorption creates a narrow therapeutic window between hyperglycemia and hypoglycemia. 2, 3

Immediate Prandial Insulin Adjustment

Tightening the Insulin-to-Carbohydrate Ratio

• Change your ratio from 1:10 to 1:6 or 1:7 (i.e., 1 unit per 6–7 g carbohydrate instead of 1 unit per 10 g) to provide 40–60% more prandial insulin coverage. 1
• For a meal containing 60 g carbohydrate, this translates to 8.5–10 units of rapid-acting insulin instead of the current 6 units. 1, 4
• The standard formula for insulin-to-carbohydrate ratio is 450 ÷ total daily dose (TDD) for rapid-acting analogs; however, in type 3c diabetes with hepatic insulin resistance, you may require ratios tighter than this formula predicts. 1, 3, 4

Titration Protocol for Prandial Insulin

• Increase each meal dose by 1–2 units every 3 days based on 2-hour post-prandial glucose readings, targeting < 180 mg/dL. 1
• If 2-hour post-prandial glucose remains > 250 mg/dL (as in your case with 351 mg/dL), increase the corresponding meal dose by 2 units immediately rather than waiting 3 days. 1
• Administer rapid-acting insulin 0–15 minutes before meals for optimal post-prandial control. 1

Basal Insulin (Lantus) Adjustment

Immediate Dose Increase

• Increase your nightly Lantus dose from 7–10 units to 12–14 units (a 2–4 unit increment) to improve fasting and between-meal glucose control. 1
• In type 3c diabetes, basal insulin typically comprises 40–50% of total daily insulin, with the remainder as prandial insulin. 1

Systematic Basal Titration

• If fasting glucose is 140–179 mg/dL, increase Lantus by 2 units every 3 days. 1
• If fasting glucose is ≥ 180 mg/dL, increase Lantus by 4 units every 3 days. 1
• Target fasting glucose range is 80–130 mg/dL. 1
• Stop basal escalation when the dose approaches 0.5 units/kg/day (approximately 35 units for a 69-kg patient) without achieving targets; at this threshold, focus on intensifying prandial insulin rather than further basal increases. 1

Accounting for Fat and Protein in Meals

• In type 3c diabetes, meals rich in fat and protein (common in patients with exocrine insufficiency who may consume higher-fat diets) require additional insulin beyond carbohydrate coverage. 5
• For every 50 g of protein in a meal, administer the same insulin dose you would give for 1 carbohydrate unit (10 g carbohydrate); this corresponds to approximately 2.15 times the carbohydrate unit for 100 g protein. 5
• Fat delays glucose absorption by 4–8 hours, necessitating extended or dual-wave boluses if using an insulin pump, or a second correction dose 3–4 hours post-meal if using injections. 1, 5

Monitoring Requirements in Type 3c Diabetes

Intensive Glucose Monitoring

• Check glucose before each meal, 2 hours after each meal, at bedtime, and overnight (3 AM) during the initial titration phase to capture the full glycemic pattern. 1, 2
• Continuous glucose monitoring (CGM) is strongly recommended in type 3c diabetes because it reveals the marked glucose variability characteristic of this condition and enables real-time dose adjustments. 2, 4
• Target glucose range: 80–180 mg/dL for most readings, with < 180 mg/dL post-prandially. 1

Hypoglycemia Vigilance

• Type 3c diabetes carries a higher risk of severe hypoglycemia than type 1 or type 2 diabetes due to impaired glucagon secretion. 2, 3
• Treat any glucose < 70 mg/dL immediately with 15 g of fast-acting carbohydrate, recheck in 15 minutes, and repeat if needed. 1
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20% before the next administration. 1
• Prescribe emergency glucagon and ensure you and your caregivers know how to use it. 1

Foundation Therapy: Metformin in Type 3c Diabetes

Rationale for Metformin

• Metformin should be the first-line therapy in type 3c diabetes because it addresses the hepatic insulin resistance characteristic of this condition and reduces pancreatic cancer risk (which is elevated in chronic pancreatitis). 3
• Metformin reduces total insulin requirements by 20–30% and yields superior glycemic control compared with insulin alone. 1, 6, 3
• Metformin has anti-neoplastic properties and should be continued even when insulin is intensified, unless specific contraindications exist (e.g., renal impairment, acute illness). 6, 3

Dosing

• Titrate metformin to at least 1000 mg twice daily (2000 mg total), with a maximum effective dose of up to 2500 mg/day. 1, 6
• Continue metformin when adding or intensifying insulin therapy; discontinuation leads to higher insulin needs and greater weight gain. 1, 6

Pancreatic Enzyme Replacement Therapy

• Pancreatic enzyme therapy should be added to prevent secondary nutritional deficiencies and metabolic bone disease, which are common in type 3c diabetes due to exocrine insufficiency. 3
• Even in the absence of overt steatorrhea, subclinical exocrine insufficiency is present in most patients with pancreatogenic diabetes. 2, 3

Expected Clinical Outcomes with Optimized Therapy

• With a tightened insulin-to-carbohydrate ratio (1:6 or 1:7) and increased basal insulin, you should achieve 2-hour post-prandial glucose < 180 mg/dL within 3–7 days. 1
• Properly implemented basal-bolus therapy enables approximately 68% of patients to achieve mean glucose < 140 mg/dL, compared with 38% using inadequate regimens. 1
• An HbA1c reduction of 1.5–2.0% is achievable within 3 months with aggressive insulin titration combined with metformin. 1, 6

Critical Pitfalls to Avoid in Type 3c Diabetes

• Do not delay insulin dose escalation when post-prandial glucose consistently exceeds 250 mg/dL; prolonged hyperglycemia increases complication risk. 1
• Do not use insulin secretagogues (sulfonylureas) in type 3c diabetes, as they increase pancreatic cancer risk and are ineffective in the setting of beta-cell destruction. 3
• Do not rely solely on correction (sliding-scale) insulin without adjusting scheduled basal and prandial doses; this reactive approach is condemned by major diabetes guidelines. 1
• Avoid over-basalization by continuing to escalate Lantus beyond 0.5 units/kg/day (approximately 35 units) without addressing post-prandial hyperglycemia; this increases hypoglycemia risk without improving control. 1
• Never discontinue metformin when intensifying insulin unless contraindicated, as this leads to higher insulin requirements and worsens outcomes. 1, 6, 3

When to Seek Urgent Medical Attention

• Contact your healthcare provider immediately if glucose remains > 300 mg/dL despite two correction doses, or if you develop nausea, vomiting, abdominal pain, or altered mental status (signs of ketoacidosis). 1
• Seek urgent evaluation if you experience recurrent severe hypoglycemia (glucose < 54 mg/dL) or hypoglycemia unawareness. 1